In this issue of Blood , Rasche et al provide the first evidence of the biological basis underlying the occurrence of false-negative scans with use of 18 F-fluorodeoxyglucose (FDG) positron… Click to show full abstract
In this issue of Blood , Rasche et al provide the first evidence of the biological basis underlying the occurrence of false-negative scans with use of 18 F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) in newly diagnosed transplant-eligible multiple myeloma (MM) patients. 1
               
Click one of the above tabs to view related content.